Explore

Trendline Trendline
Sri Lanka Ayurveda Department License Does Not Meet U.S. FDA Requirements for Herbal Products

Sri Lanka Ayurveda Department License Does Not Meet U.S. FDA Requirements for Herbal Products

Sri Lanka Ayurveda Department License Does Not Meet U.S. FDA Requirements for Herbal Products
Rapid Read Rapid Read
FDA Issues Class II Recall for Clear Eyes Maximum Itchy Eye Relief Drops

FDA Issues Class II Recall for Clear Eyes Maximum Itchy Eye Relief Drops

The U.S. Food and Drug Administration (FDA) has upgraded a recall for nearly 40,000 bottles of Clear Eyes Maximum Itchy Eye Relief drops to a Class II classification. This recall, initiated by Prestige Brand Holdings, affects 15 mL bottles with an expiration date of September 30, 2027. The specific lot code is 2552A, NDC 67172-999-01, and UPC 6 78112 65920 3. The reason for the recall is a 'lack of assurance of sterility,' meaning the eye drops could potentially be contaminated with bacteria or fungi. While the FDA states that medical problems resulting from exposure would likely be temporary and treatable, consumers are advised to stop using the product immediately. The affected eye drops were distributed nationwide and sold at major retailers including Amazon, CVS, Kroger, Walgreens, Target, Menards, and Dollar General.
Rapid Read Rapid Read
U.S. Lawmakers Urge FDA to Tighten Regulations on Chinese Clinical Trial Data Following Patient Deaths

U.S. Lawmakers Urge FDA to Tighten Regulations on Chinese Clinical Trial Data Following Patient Deaths

Two Republican U.S. Representatives, John Moolenaar of Michigan and Ben Cline of Virginia, have sent a letter to the acting commissioner of the U.S. Food and Drug Administration (FDA), Kyle Diamantas, demanding stricter regulations on the use of Chinese clinical trial data in U.S. drug development and approval processes. This demand follows recent reports of three patient deaths in China involving experimental gene therapies, including two children. The lawmakers highlighted concerns that the U.S. is accepting unverified Chinese clinical data, potentially exposing patients to undue risks. They specifically requested that the FDA not accept clinical trial data generated in China for Investigational New Drug (IND) applications, New Drug Applications (NDA), or Biologics License Applications (BLA), unless the trial sites have undergone an FDA on-site inspection within 12 months prior to the application submission. Additionally, they called for a comprehensive evaluation of the U.S. reliance on Chinese-initiate...
Rapid Read Rapid Read
Researchers Uncover Unexpected Benefits and Risks of GLP-1 Weight Loss Drugs

Researchers Uncover Unexpected Benefits and Risks of GLP-1 Weight Loss Drugs

Researchers, including Dr. Steven Heymsfield from the Pennington Biomedical Research Center, have identified both anticipated and surprising benefits and risks associated with GLP-1 weight loss drugs. While these drugs have been used for approximately five years, new findings suggest advantages beyond weight loss, such as improved arthritis symptoms, reduced pain and inflammation, and a decreased desire for alcohol. Studies indicate that GLP-1s can lower the risk of heart attacks, cardiovascular disease, and mortality, partly due to their anti-inflammatory properties, not solely weight reduction. However, concerns have emerged regarding adverse effects, including vitamin deficiencies like scurvy due to altered eating habits, a loss of enjoyment in eating (hedonia), and muscle and bone loss. Heymsfield noted that some patients experience a significant reduction in 'food noise,' which, while often beneficial, can become overly pronounced. The potential for off-label prescribing for inflammation in individual...
Trendline Trendline
Prebiotic Sodas Offer Alternative to Sugary Drinks but Lack Comprehensive Nutritional Benefits of Whole Foods

Prebiotic Sodas Offer Alternative to Sugary Drinks but Lack Comprehensive Nutritional Benefits of Whole Foods

Prebiotic Sodas Offer Alternative to Sugary Drinks but Lack Comprehensive Nutritional Benefits of Whole Foods
USA Today USA Today
Pittsburgh reports first case of measles. See exposures, US data

Pittsburgh reports first case of measles. See exposures, US data

A person with measles visited Pittsburgh twice in August, exposing people at UPMC Children's Hospital.
Trendline Trendline
Nootropic Supplements: Safety, Efficacy, and Onset Times for Cognitive Enhancement

Nootropic Supplements: Safety, Efficacy, and Onset Times for Cognitive Enhancement

Nootropic Supplements: Safety, Efficacy, and Onset Times for Cognitive Enhancement
Rapid Read Rapid Read
FDA Publishes White Paper on Digitally Derived Measures for Clinical Investigations

FDA Publishes White Paper on Digitally Derived Measures for Clinical Investigations

The U.S. Food and Drug Administration (FDA) has released a white paper titled “Key Considerations for the Development and Use of Digitally Derived Measures for Clinical Investigations.” This document outlines important considerations for leveraging digital health technologies (DHTs) to collect data in clinical trials. The FDA emphasizes that DHTs, particularly those enhanced by artificial intelligence, can continuously capture health information in real-time and within a person's daily life, expanding beyond traditional periodic clinic visits. This initiative aligns with the FDA’s mission to protect and advance public health by supporting innovation in medical product development. The white paper aims to guide the development and use of digitally derived measures (DDMs) as outcomes in clinical investigations, advancing one of the FDA’s priorities under Public Health Pillar 1: strengthening the use of emerging technologies.
Rapid Read Rapid Read
GLP-1 Drugs Reshape U.S. Healthcare Landscape, Prompting Strategic Reset for Providers and Payers

GLP-1 Drugs Reshape U.S. Healthcare Landscape, Prompting Strategic Reset for Providers and Payers

GLP-1 weight-loss drugs are significantly altering the U.S. healthcare system, prompting a strategic reset for providers, insurers, and investors, according to a new Wells Fargo report. These drugs, which have seen a more than 140% increase in use from 2022 to 2024, are shifting the focus from treating obesity-related complications to prevention. This shift is evident in the 34.1% decline in metabolic bariatric surgery volumes during the same period. GLP-1s are also demonstrating the ability to prevent costly complications, such as reducing major adverse cardiovascular events by 20% in high-risk populations. The report indicates that while GLP-1s offer long-term health benefits and potential reductions in healthcare utilization, they present significant near-term drug costs for employers, payers, and Medicare. Employer health costs are projected to rise by 9.5% in 2027, partly due to these drugs.
Trendline Trendline
Daily Blueberry Consumption Linked to Enhanced Health Benefits and Fitness Recovery

Daily Blueberry Consumption Linked to Enhanced Health Benefits and Fitness Recovery

Daily Blueberry Consumption Linked to Enhanced Health Benefits and Fitness Recovery
Rapid Read Rapid Read
Medical Compression Socks Offer Significant Health Benefits for U.S. Consumers

Medical Compression Socks Offer Significant Health Benefits for U.S. Consumers

Medical compression socks are gaining recognition for their ability to support blood flow, reduce leg swelling, and prevent vein problems. These specialized garments apply graduated pressure, strongest at the ankle and gradually decreasing upwards, to assist veins in returning blood to the heart against gravity. This mechanism helps alleviate symptoms such as ankle swelling, aching, and tired legs, and can also mitigate discomfort associated with mild varicose veins. Unlike ordinary tight socks, medical-grade compression socks are available in defined compression ranges and are designed for specific health needs, including managing swelling, supporting inefficient veins, or reducing clot risk during periods of limited movement. Healthcare professionals often recommend them for individuals with mild to moderate lower-leg swelling, varicose vein symptoms, chronic venous insufficiency, or lymphedema. They are also commonly used during pregnancy to address leg swelling and discomfort, and by individuals whose ...
Rapid Read Rapid Read
Prestige Brand Holdings Recalls 40,000 Bottles of Clear Eyes Maximum Itchy Eye Relief Due to Sterility Concerns

Prestige Brand Holdings Recalls 40,000 Bottles of Clear Eyes Maximum Itchy Eye Relief Due to Sterility Concerns

Prestige Brand Holdings has voluntarily recalled nearly 40,000 bottles of its Clear Eyes Maximum Itchy Eye Relief eye drops nationwide, including in Rhode Island. The U.S. Food and Drug Administration (FDA) reported that the recall is due to a "lack of assurance of sterility." The affected products are 15mL bottles with an expiration date of September 30, 2027. The FDA has classified this as a Class II recall, indicating that the use of or exposure to the product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote. Consumers are advised not to use the recalled eye drops as they could be contaminated or cause infection. Prestige Brand Holdings, a consumer healthcare company known for products like Dramamine and Breathe Right, has not yet responded to requests for comment.